Which has higher valuation and earnings, GALT or FTH?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is GALT or FTH more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media favor GALT or FTH?

In the previous week, Galectin Therapeutics had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Galectin Therapeutics and 5 mentions for Sensei Biotherapeutics. Galectin Therapeutics' average media sentiment score of 1.05 beat Sensei Biotherapeutics' score of 0.32 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GALT or ACRS?

In the previous week, Galectin Therapeutics had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Galectin Therapeutics and 1 mentions for Aclaris Therapeutics. Galectin Therapeutics' average media sentiment score of 1.05 beat Aclaris Therapeutics' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, IMMX or GALT?

Immix Biopharma is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immix Biopharma N/A N/A -$29.44M -$0.88 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A

Is IMMX or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -38.44% -34.72% Galectin Therapeutics N/A N/A -176.83%

Does the media favor IMMX or GALT?

In the previous week, Galectin Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Galectin Therapeutics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat Galectin Therapeutics' score of 1.05 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GALT or RIGL?

In the previous week, Rigel Pharmaceuticals had 7 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Rigel Pharmaceuticals and 6 mentions for Galectin Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat Galectin Therapeutics' score of 1.05 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Galectin Therapeutics (GALT) Competitors

$3.68 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

GALT vs. FTH, ACRS, PHAR, IMMX, and RIGL

Should you buy Galectin Therapeutics stock or one of its competitors? Galectin Therapeutics's main competitors and comparable companies include Sensei Biotherapeutics (FTH), Aclaris Therapeutics (ACRS), Pharming Group (PHAR), Immix Biopharma (IMMX), and Rigel Pharmaceuticals (RIGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Galectin Therapeutics compare to Sensei Biotherapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Galectin Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 198.91%. Sensei Biotherapeutics has a consensus target price of $55.00, indicating a potential upside of 71.88%. Given Galectin Therapeutics' higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galectin Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

Galectin Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Galectin Therapeutics had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 6 mentions for Galectin Therapeutics and 5 mentions for Sensei Biotherapeutics. Galectin Therapeutics' average media sentiment score of 1.05 beat Sensei Biotherapeutics' score of 0.32 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Galectin Therapeutics beats Sensei Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Aclaris Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galectin Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Galectin Therapeutics' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

Galectin Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

In the previous week, Galectin Therapeutics had 5 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Galectin Therapeutics and 1 mentions for Aclaris Therapeutics. Galectin Therapeutics' average media sentiment score of 1.05 beat Aclaris Therapeutics' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 198.91%. Aclaris Therapeutics has a consensus target price of $11.50, indicating a potential upside of 79.41%. Given Galectin Therapeutics' higher probable upside, research analysts clearly believe Galectin Therapeutics is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Galectin Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Aclaris Therapeutics	$7.83M	114.46	-$64.92M	-$0.58	N/A

Summary

Galectin Therapeutics beats Aclaris Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Galectin Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pharming Group has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

Pharming Group currently has a consensus price target of $38.67, indicating a potential upside of 226.30%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 198.91%. Given Pharming Group's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pharming Group is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pharming Group has a net margin of 2.51% compared to Galectin Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Galectin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Galectin Therapeutics	N/A	N/A	-176.83%

In the previous week, Galectin Therapeutics had 6 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Galectin Therapeutics and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.93 beat Galectin Therapeutics' score of 1.05 indicating that Pharming Group is being referred to more favorably in the media.

Company	Overall Sentiment
Pharming Group	Very Positive
Galectin Therapeutics	Positive

Pharming Group has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.23	$2.85M	$0.12	98.75
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Summary

Pharming Group beats Galectin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Immix Biopharma presently has a consensus price target of $21.29, suggesting a potential upside of 55.83%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 198.91%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Immix Biopharma is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

In the previous week, Galectin Therapeutics had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 6 mentions for Galectin Therapeutics and 3 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.19 beat Galectin Therapeutics' score of 1.05 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
Galectin Therapeutics	N/A	N/A	-176.83%

Immix Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Galectin Therapeutics beats Immix Biopharma on 8 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to Rigel Pharmaceuticals?

Galectin Therapeutics (NASDAQ:GALT) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 198.91%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 28.57%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Rigel Pharmaceuticals	$276.79M	3.07	$367.02M	$16.32	2.81

Galectin Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 7 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Rigel Pharmaceuticals and 6 mentions for Galectin Therapeutics. Rigel Pharmaceuticals' average media sentiment score of 1.15 beat Galectin Therapeutics' score of 1.05 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 116.30% compared to Galectin Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Galectin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Summary

Rigel Pharmaceuticals beats Galectin Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$242.37M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-8.56	11.68	272.91	24.33
Price / Sales	N/A	1,240.56	594.70	76.14
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	-1.85	17.36	11.26	6.42
Net Income	-$30.84M	-$22.72M	$3.47B	$348.89M
7 Day Performance	4.84%	2.76%	2.19%	0.51%
1 Month Performance	6.05%	9.66%	7.62%	4.84%
1 Year Performance	-10.24%	54.97%	25.17%	17.04%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	2.2206 of 5 stars	$3.68 flat	$11.00 +198.9%	-10.2%	$242.37M	N/A	N/A	9	Positive News
FTH Sensei Biotherapeutics	4.3866 of 5 stars	$33.95 +3.6%	$54.90 +61.7%	N/A	$877.17M	N/A	N/A	40	Analyst Forecast Gap Up
ACRS Aclaris Therapeutics	1.7733 of 5 stars	$6.16 +4.0%	$11.50 +86.8%	+256.1%	$862.13M	$7.83M	N/A	100
PHAR Pharming Group	3.9427 of 5 stars	$11.59 -1.7%	$38.67 +233.6%	-13.5%	$820.41M	$376.13M	96.59	280	Gap Down
IMMX Immix Biopharma	2.8162 of 5 stars	$11.49 +1.3%	$21.29 +85.3%	+523.7%	$820.35M	N/A	N/A	9	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. FTH, ACRS, PHAR, IMMX, and RIGL

How does Galectin Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Galectin Therapeutics compare to Aclaris Therapeutics?

Summary

How does Galectin Therapeutics compare to Pharming Group?

Summary

How does Galectin Therapeutics compare to Immix Biopharma?

Summary

How does Galectin Therapeutics compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. FTH, ACRS, PHAR, IMMX, and RIGL

How does Galectin Therapeutics compare to Sensei Biotherapeutics?

Do analysts prefer GALT or FTH?

Which has higher valuation and earnings, GALT or FTH?

Do institutionals and insiders believe in GALT or FTH?

Which has more risk & volatility, GALT or FTH?

Is GALT or FTH more profitable?

Does the media favor GALT or FTH?

Summary

How does Galectin Therapeutics compare to Aclaris Therapeutics?

Do insiders & institutionals believe in GALT or ACRS?

Is GALT or ACRS more profitable?

Which has more volatility and risk, GALT or ACRS?

Does the media refer more to GALT or ACRS?

Do analysts prefer GALT or ACRS?

Which has stronger valuation & earnings, GALT or ACRS?

Summary

How does Galectin Therapeutics compare to Pharming Group?

Do insiders and institutionals hold more shares of PHAR or GALT?

Which has more volatility & risk, PHAR or GALT?

Do analysts prefer PHAR or GALT?

Is PHAR or GALT more profitable?

Does the media favor PHAR or GALT?

Which has preferable valuation & earnings, PHAR or GALT?

Summary

How does Galectin Therapeutics compare to Immix Biopharma?

Do analysts prefer IMMX or GALT?

Which has better valuation & earnings, IMMX or GALT?

Does the media favor IMMX or GALT?

Is IMMX or GALT more profitable?

Which has more volatility and risk, IMMX or GALT?

Do institutionals and insiders have more ownership in IMMX or GALT?

Summary

How does Galectin Therapeutics compare to Rigel Pharmaceuticals?

Do insiders and institutionals have more ownership in GALT or RIGL?

Do analysts rate GALT or RIGL?

Which has higher earnings and valuation, GALT or RIGL?

Which has more risk & volatility, GALT or RIGL?

Does the media favor GALT or RIGL?

Is GALT or RIGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools